Glaucoma Trial, Recruiting NCT07281391 Sponsor: Mann Eye Institute Condition: Glaucoma
Back to Glaucoma

Glaucoma Trial, Recruiting

NCT07281391
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are an adult who has been diagnosed with pigmentary dispersion syndrome (a condition where pigment cells shed into the eye) with higher-than-normal eye pressure, or mild to moderate pigmentary glaucoma with signs of damage to the optic nerve and vision.
  • Your eye pressure (when not on medication, or after stopping medication) is measured between 18 and 34 mmHg.
  • The thickness of the clear front surface of your eye (the cornea) measures between 480 and 600 micrometres.
  • You are able to stop any current eye pressure-lowering medications for a period before the trial and attend all required follow-up appointments.

Who may not be able to join:

  • You have previously had surgery on the eye involving cuts or incisions to treat glaucoma, or other glaucoma-related procedures in that eye.
  • You have had laser treatment for glaucoma (called laser trabeculoplasty) in the last 3 years.
  • You have had previous surgery inside the eye or surgery to correct your vision (such as LASIK), unless it was cataract surgery performed more than 2 years ago.
  • You are expecting to need cataract surgery during the period of the trial.
  • You have a history of inflammation or infection in the eye.
  • You have any other type of glaucoma caused by another condition, including a type called exfoliative glaucoma.
  • You are unable to receive the specific treatment being studied in this trial (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Alex Hacopian, MD, Mann Eye Institute

Phone: 713-580-2500

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Mann Eye Institute
Registry
ClinicalTrials.gov
Start date
19 March 2026
Est. completion
1 April 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Mean washed-out IOP change post-DSLT compared to washed-out baseline IOP

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov